{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:51:37Z","timestamp":1791154297520,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41440-026-02773-8","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:34:06Z","timestamp":1787110446000},"page":"2892-2903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aldosterone-renin ratio and plasma renin activity as biomarkers for treatment response in resistant hypertension"],"prefix":"10.1038","volume":"49","author":[{"given":"Kyeong-Hyeon","family":"Chun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ok","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiWung","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wook Bum","family":"Pyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyun","family":"Ihm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungha","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2773_CR1","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72:e53\u2013e90.","journal-title":"Hypertension"},{"key":"2773_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"2773_CR3","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.2025.5129","volume":"333","author":"CJ Lee","year":"2025","unstructured":"Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, et al. Spironolactone vs amiloride for resistant hypertension: a randomized clinical trial. JAMA. 2025;333:2073\u201382.","journal-title":"JAMA"},{"key":"2773_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diab Endocrinol. 2018;6:464\u201375.","journal-title":"Lancet Diab Endocrinol"},{"key":"2773_CR5","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"key":"2773_CR6","doi-asserted-by":"publisher","unstructured":"Cho JS, Jung JH, Kwon W, Chung WB, Ihm SH. High plasma renin and aldosterone levels are associated with a unique phenotype in primary hypertension. Korean Circ J. 2025 (e-pub ahead of print 20250724;https:\/\/doi.org\/10.4070\/kcj.2025.0140).","DOI":"10.4070\/kcj.2025.0140"},{"key":"2773_CR7","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"2773_CR8","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, et al. Primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2025;110:2453\u201395.","journal-title":"J Clin Endocrinol Metab"},{"key":"2773_CR9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1152\/physrev.00026.2015","volume":"96","author":"M Stowasser","year":"2016","unstructured":"Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev. 2016;96:1327\u201384.","journal-title":"Physiol Rev"},{"key":"2773_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2773_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension. 2012;60:618\u201324.","journal-title":"Hypertension"},{"key":"2773_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0092-8674(01)00241-0","volume":"104","author":"RP Lifton","year":"2001","unstructured":"Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545\u201356.","journal-title":"Cell"},{"key":"2773_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/ncpneph0309","volume":"2","author":"VD Garovic","year":"2006","unstructured":"Garovic VD, Hilliard AA, Turner ST. Monogenic forms of low-renin hypertension. Nat Clin Pr Nephrol. 2006;2:624\u201330.","journal-title":"Nat Clin Pr Nephrol"},{"key":"2773_CR14","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA. 2025;333:71\u20134.","DOI":"10.1001\/jama.2024.21972"},{"key":"2773_CR15","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393:1363\u201374.","journal-title":"N Engl J Med"},{"key":"2773_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159\u201364.","journal-title":"Arch Intern Med"},{"key":"2773_CR17","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"P Mulatero","year":"2004","unstructured":"Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"2773_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1055\/s-0035-1548868","volume":"47","author":"A Viola","year":"2015","unstructured":"Viola A, Monticone S, Burrello J, Buffolo F, Lucchiari M, Rabbia F, et al. Renin and aldosterone measurements in the management of arterial hypertension. Horm Metab Res. 2015;47:418\u201326.","journal-title":"Horm Metab Res"},{"key":"2773_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.ajkd.2019.03.427","volume":"74","author":"BF Palmer","year":"2019","unstructured":"Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis: core curriculum 2019. Am J Kidney Dis. 2019;74:682\u201395.","journal-title":"Am J Kidney Dis"},{"key":"2773_CR20","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1097\/HJH.0b013e32834ab46a","volume":"29","author":"M Satoh","year":"2011","unstructured":"Satoh M, Kikuya M, Ohkubo T, Mori T, Metoki H, Hashimoto T, et al. Aldosterone-to-renin ratio and nocturnal blood pressure decline in a general population: the Ohasama study. J Hypertens. 2011;29:1940\u20137.","journal-title":"J Hypertens"},{"key":"2773_CR21","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41440-025-02297-7","volume":"48","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Jones ESW, Lihn AS, et al. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res. 2025;48:2911\u201323.","journal-title":"Hypertens Res"},{"key":"2773_CR22","first-page":"e568","volume":"152","author":"J Flack","year":"2025","unstructured":"Flack J, Azizi M, Brown J, Dwyer J, Jones E, Kurlyandskaya R, et al. Effect of baxdrostat on 24-hour average ambulatory blood pressure in patients with resistant hypertension: the Bax24 trial. Circulation. 2025;152:e568 [Abstract].","journal-title":"Circulation"},{"key":"2773_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(07)61538-4","volume":"370","author":"J Boggia","year":"2007","unstructured":"Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bj\u00f6rklund-Bodeg\u00e5rd K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370:1219\u201329.","journal-title":"Lancet"},{"key":"2773_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1291\/hypres.30.143","volume":"30","author":"S Hoshide","year":"2007","unstructured":"Hoshide S, Ishikawa J, Eguchi K, Ojima T, Shimada K, Kario K. Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure. Hypertens Res. 2007;30:143\u20139.","journal-title":"Hypertens Res"},{"key":"2773_CR25","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIRCULATIONAHA.120.049730","volume":"142","author":"K Kario","year":"2020","unstructured":"Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, et al. Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP Study. Circulation. 2020;142:1810\u201320.","journal-title":"Circulation"},{"key":"2773_CR26","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1097\/HJH.0b013e3283395267","volume":"28","author":"K Kario","year":"2010","unstructured":"Kario K, Hoshide S, Shimizu M, Yano Y, Eguchi K, Ishikawa J, et al. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2010;28:1574\u201383.","journal-title":"J Hypertens"},{"key":"2773_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/HYPERTENSIONAHA.118.10971","volume":"71","author":"K Kario","year":"2018","unstructured":"Kario K. Nocturnal hypertension: new technology and evidence. Hypertension. 2018;71:997\u20131009.","journal-title":"Hypertension"},{"key":"2773_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1161\/HYPERTENSIONAHA.124.24026","volume":"82","author":"J Liu","year":"2025","unstructured":"Liu J, Li Y, Asayama K, Zhang XJ, Cheng HM, Park S, et al. Asian Expert Consensus on Nocturnal Hypertension Management. Hypertension. 2025;82:945\u201356.","journal-title":"Hypertension"},{"key":"2773_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10641963.2018.1481422","volume":"41","author":"EH Choo","year":"2019","unstructured":"Choo EH, Ha KH, Lee SW, Kim HC, Park S, Lee HY, et al. Low plasma renin activity is an independent predictor of near-term incidence of hypertension in Asian populations. Clin Exp Hypertens. 2019;41:330\u20135.","journal-title":"Clin Exp Hypertens"},{"key":"2773_CR30","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1097\/HJH.0000000000003706","volume":"42","author":"G Loo","year":"2024","unstructured":"Loo G, Puar T, Foo R, Ong TK, Wang TD, Nguyen QN, et al. Unique characteristics of Asians with hypertension: what is known and what can be done? J Hypertens. 2024;42:1482\u20139.","journal-title":"J Hypertens"},{"key":"2773_CR31","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000257","volume":"82","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82:e212\u2013e316.","journal-title":"Hypertension"},{"key":"2773_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"2773_CR33","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"2773_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/HYPERTENSIONAHA.124.23985","volume":"82","author":"SMJ Cho","year":"2025","unstructured":"Cho SMJ, Urbut S, Ruan Y, Bhatnagar A, Ganesh S, Hornsby WE, et al. East and South Asian-specific blood pressure trajectories and cardiovascular disease. Hypertension. 2025;82:520\u201331.","journal-title":"Hypertension"},{"key":"2773_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/jch.14099","volume":"23","author":"Y Turana","year":"2021","unstructured":"Turana Y, Tengkawan J, Chia YC, Nathaniel M, Wang JG, Sukonthasarn A, et al. Hypertension and stroke in Asia: a comprehensive review from HOPE Asia. J Clin Hypertens (Greenwich). 2021;23:513\u201321.","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02773-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02773-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02773-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:02:48Z","timestamp":1791151368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02773-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2773"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02773-8","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Supplementary Information file has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}